Maze Therapeutics price to book ratio MAZE
Market value divided by the book value of the company's net assets, since 2025.
- Today, Nov 2, 2026
- 3.7×
- Peer median
- 5.4×
Maze Therapeutics' price to book ratio is 3.7× as of Nov 2, 2026.
The median for 9 biotech stocks of a similar size is 5.4×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 3.7× | 2.8× | 6.4× |
| 2025 | 5.3× | 1.4× | 5.5× |
Against its peers
Companies in Biotechnology nearest Maze Therapeutics' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| MAZEMaze Therapeutics | 3.7× |
| VCELVericel | 5.6× |
| ADMAAdma Biologics | 6.1× |
| MGTXMeiraGTx | 4.2× |
| KRYSKrystal Biotech | 6.4× |
| RGENRepligen | 4.6× |
| TECHBIO-TECHNE | 5.4× |
| PLXProtalix BioTherapeutics | 2.9× |
| HALOHalozyme Therapeutics | 102× |
| NBIXNeurocrine Biosciences | 4.0× |
| Peer median | 5.4× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Maze Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.